Using a cascade of care framework to identify gaps in access to medications for alcohol use disorder in British Columbia, Canada

Abstract

AbstractBackground and aimsDespite the significant burden of alcohol use disorder (AUD) and availability of safe and effective medications for AUD (MAUD), population‐level estimates of access and engagement in AUD‐related care are limited. The aims of this study were to generate a cascade of care for AUD in British Columbia (BC), Canada, and to estimate the impacts of MAUD on health outcomes.DesignThis was a retrospective population‐based cohort study using linked administrative health data.SettingBritish Columbia, Canada, 2015–2019.ParticipantsUsing a 20% random sample of BC residents, we identified 7231 people with moderate‐to‐severe alcohol use disorder (PWAUD; overall prevalence = 0.7%).MeasurementsWe developed a six‐stage AUD cascade (from diagnosis to ≥6 months retention in MAUD) among PWAUD. We evaluated trends over time and estimated the impacts of access to MAUD on AUD‐related hospitalizations, emergency department visits and death.FindingsBetween 2015 and 2019, linkage to AUD‐related care decreased (from 80.4% to 46.5%). However, rates of MAUD initiation (11.4% to 24.1%) and retention for ≥1 (7.0% to 18.2%), ≥3 (1.2% to 4.3%) or ≥6 months (0.2% to 1.6%) increased significantly. In adjusted analyses, access to MAUD was associated with reduced odds of experiencing any AUD‐related adverse outcomes, with longer retention in MAUD showing a trend to greater odds reduction: adjusted odds ratio (95% CI) ranging from 0.59 (0.48–0.71) for MAUD retention <1 month to 0.37 (0.21–0.67) for ≥6 months retention.ConclusionsAccess to medications for alcohol use disorder among people with moderate‐to‐severe alcohol use disorder in British Colombia, Canada increased between 2015 and 2019; however, initiation and retention remained low. There was a trend between longer retention in medications for alcohol use disorder and greater reductions in the odds of experiencing alcohol use disorder‐related adverse outcomes.